IL17A and chronic obstructive pulmonary disease: The inhibitors for NF-κB (Helenalin) and PI3K (PI-103) significantly attenuated CSE-induced IL-17A (DMSO: 3.1 ± 1.2 folds; Helenalin: 0.7 ± 0.2 fold, P < 0.05; PI-103: 1.0 ± 0.3 fold, P < 0.05) and IL-17 F (DMSO: 2.0 ± 0.2 folds; Helenalin: 1.2 ± 0.2 fold, P < 0.01; PI-103: 1.1 ± 0.3 fold, P < 0.05) expression from lung tissue of non-COPD subjects (Figure 5).